Literature DB >> 26799472

TSH Receptor Cleavage Into Subunits and Shedding of the A-Subunit; A Molecular and Clinical Perspective.

Basil Rapoport1, Sandra M McLachlan1.   

Abstract

The TSH receptor (TSHR) on the surface of thyrocytes is unique among the glycoprotein hormone receptors in comprising two subunits: an extracellular A-subunit, and a largely transmembrane and cytosolic B-subunit. Unlike its ligand TSH, whose subunits are encoded by two genes, the TSHR is expressed as a single polypeptide that subsequently undergoes intramolecular cleavage into disulfide-linked subunits. Cleavage is associated with removal of a C-peptide region, a mechanism similar in some respects to insulin cleavage into disulfide linked A- and B-subunits with loss of a C-peptide region. The potential pathophysiological importance of TSHR cleavage into A- and B-subunits is that some A-subunits are shed from the cell surface. Considerable experimental evidence supports the concept that A-subunit shedding in genetically susceptible individuals is a factor contributing to the induction and/or affinity maturation of pathogenic thyroid-stimulating autoantibodies, the direct cause of Graves' disease. The noncleaving gonadotropin receptors are not associated with autoantibodies that induce a "Graves' disease of the gonads." We also review herein current information on the location of the cleavage sites, the enzyme(s) responsible for cleavage, the mechanism by which A-subunits are shed, and the effects of cleavage on receptor signaling.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26799472      PMCID: PMC4823380          DOI: 10.1210/er.2015-1098

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  136 in total

Review 1.  Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure.

Authors:  Theo Klein; Rainer Bischoff
Journal:  J Proteome Res       Date:  2010-10-14       Impact factor: 4.466

2.  Hyperthyroid monkeys: a nonhuman primate model of experimental Graves' disease.

Authors:  Y Wang; L P Wu; J Fu; H J Lv; X Y Guan; L Xu; P Chen; C Q Gao; P Hou; M J Ji; B Y Shi
Journal:  J Endocrinol       Date:  2013-10-28       Impact factor: 4.286

3.  Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites.

Authors:  G D Chazenbalk; K Tanaka; Y Nagayama; A Kakinuma; J C Jaume; S M McLachlan; B Rapoport
Journal:  Endocrinology       Date:  1997-07       Impact factor: 4.736

Review 4.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

5.  Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization.

Authors:  Monika Hartmann; Liseth M Parra; Anne Ruschel; Christina Lindner; Helen Morrison; Andreas Herrlich; Peter Herrlich
Journal:  J Biol Chem       Date:  2015-04-29       Impact factor: 5.157

6.  Evidence that the thyroid-stimulating hormone (TSH) receptor transmembrane domain influences kinetics of TSH binding to the receptor ectodomain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

7.  Differential requirement of signal transducer and activator of transcription-4 (Stat4) and Stat6 in a thyrotropin receptor-289-adenovirus-induced model of Graves' hyperthyroidism.

Authors:  Kimberly J Land; Prathyusha Gudapati; Mark H Kaplan; Gattadahalli S Seetharamaiah
Journal:  Endocrinology       Date:  2005-09-29       Impact factor: 4.736

8.  An N-linked glycosylation motif from the noncleaving luteinizing hormone receptor substituted for the homologous region (Gly367 to Glu369) of the thyrotropin receptor prevents cleavage at its second, downstream site.

Authors:  A Kakinuma; G D Chazenbalk; K Tanaka; Y Nagayama; S M McLachlan; B Rapoport
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

9.  Evidence that the thyrotropin receptor protease is membrane-associated and is not within lipid rafts.

Authors:  Francesco Latrofa; Gregorio D Chazenbalk; Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2004-10       Impact factor: 6.568

Review 10.  Autophagy and other vacuolar protein degradation mechanisms.

Authors:  P O Seglen; P Bohley
Journal:  Experientia       Date:  1992-02-15
View more
  24 in total

1.  Nanoparticles Bearing TSH Receptor Protein and a Tolerogenic Molecule Do Not Induce Immune Tolerance but Exacerbate Thyroid Autoimmunity in hTSHR/NOD.H2h4 Mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Basil Rapoport
Journal:  J Immunol       Date:  2019-04-03       Impact factor: 5.422

Review 2.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

3.  High-level intrathymic thyrotrophin receptor expression in thyroiditis-prone mice protects against the spontaneous generation of pathogenic thyrotrophin receptor autoantibodies.

Authors:  S M McLachlan; H A Aliesky; B Banuelos; S Lesage; R Collin; B Rapoport
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

Review 4.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

5.  A Mouse Thyrotropin Receptor A-Subunit Transgene Expressed in Thyroiditis-Prone Mice May Provide Insight into Why Graves' Disease Only Occurs in Humans.

Authors:  Sandra M McLachlan; Holly A Aliesky; Basil Rapoport
Journal:  Thyroid       Date:  2019-07-03       Impact factor: 6.568

Review 6.  TSHR as a therapeutic target in Graves' disease.

Authors:  Terry Smith
Journal:  Expert Opin Ther Targets       Date:  2017-02-06       Impact factor: 6.902

7.  Hormone- and antibody-mediated activation of the thyrotropin receptor.

Authors:  Jia Duan; Peiyu Xu; Xiaodong Luan; Yujie Ji; Xinheng He; Ning Song; Qingning Yuan; Ye Jin; Xi Cheng; Hualiang Jiang; Jie Zheng; Shuyang Zhang; Yi Jiang; H Eric Xu
Journal:  Nature       Date:  2022-08-08       Impact factor: 69.504

Review 8.  A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocrine       Date:  2019-09-27       Impact factor: 3.633

9.  Implications of an Improved Model of the TSH Receptor Transmembrane Domain (TSHR-TMD-TRIO).

Authors:  Mihaly Mezei; Rauf Latif; Bhaskar Das; Terry F Davies
Journal:  Endocrinology       Date:  2021-07-01       Impact factor: 4.736

10.  2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Authors:  George J Kahaly; Luigi Bartalena; Lazlo Hegedüs; Laurence Leenhardt; Kris Poppe; Simon H Pearce
Journal:  Eur Thyroid J       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.